EyePoint, Inc. (EYPT)
2.99
-0.15
(-4.78%)
USD |
NASDAQ |
Oct 16, 16:00
3.09
+0.10
(+3.34%)
After-Hours: 20:00
EyePoint Free Cash Flow : -271.28M for June 30, 2026
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| June 30, 2026 | -271.28M |
| March 31, 2026 | -271.54M |
| December 31, 2025 | -243.39M |
| September 30, 2025 | -213.59M |
| June 30, 2025 | -194.04M |
| March 31, 2025 | -151.31M |
| December 31, 2024 | -130.28M |
| September 30, 2024 | -118.04M |
| June 30, 2024 | -94.36M |
| March 31, 2024 | -16.65M |
| December 31, 2023 | -1.608M |
| September 30, 2023 | 9.211M |
| June 30, 2023 | 11.80M |
| March 31, 2023 | -64.17M |
| December 31, 2022 | -67.16M |
| September 30, 2022 | -70.65M |
| June 30, 2022 | -64.23M |
| March 31, 2022 | -55.46M |
| December 31, 2021 | -50.25M |
| September 30, 2021 | -27.88M |
| June 30, 2021 | -18.96M |
| March 31, 2021 | -13.54M |
| December 31, 2020 | -14.80M |
| September 30, 2020 | -31.99M |
| June 30, 2020 | -47.77M |
| Date | Value |
|---|---|
| March 31, 2020 | -59.76M |
| December 31, 2019 | -56.91M |
| September 30, 2019 | |
| June 30, 2019 | |
| March 31, 2019 | |
| December 31, 2018 | |
| September 30, 2018 | |
| June 30, 2018 | |
| March 31, 2018 | |
| June 30, 2017 | -20.64M |
| March 31, 2017 | -20.45M |
| December 31, 2016 | -20.23M |
| September 30, 2016 | -18.41M |
| June 30, 2016 | -16.43M |
| March 31, 2016 | -15.13M |
| December 31, 2015 | -14.80M |
| September 30, 2015 | 9.632M |
| June 30, 2015 | 10.14M |
| March 31, 2015 | 10.27M |
| December 31, 2014 | 12.36M |
| September 30, 2014 | -11.13M |
| June 30, 2014 | -10.92M |
| March 31, 2014 | -11.36M |
| December 31, 2013 | -11.43M |
| September 30, 2013 | -10.97M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| Ocular Therapeutix, Inc. | -255.10M |
| Corcept Therapeutics, Inc. | 106.92M |
| Eli Lilly & Co. | 13.56B |
| Regeneron Pharmaceuticals, Inc. | 3.575B |
| Nuvation Bio, Inc. | -128.92M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -62.35M |
| Cash from Investing (Quarterly) | 75.10M |
| Cash from Financing (Quarterly) | 19.99M |
| Free Cash Flow Per Share (Quarterly) | -0.7343 |
| Free Cash Flow to Equity (Quarterly) | -63.60M |
| Free Cash Flow to Firm (Quarterly) | -63.55M |
| Free Cash Flow Yield | -111.4% |